Back |
home / stock / btai / btai message board
Subject | By | Source | When |
---|---|---|---|
$BTAI Yesterday Canaccord Genuity reaffirmed their buy rating | realfast95 | investorshub | 04/26/2022 10:55:31 AM |
Chart Bullish engulfing | realfast95 | investorshub | 04/25/2022 8:54:06 PM |
is it safe? | realfast95 | investorshub | 04/25/2022 8:11:24 PM |
EMA meeting this week for Igalmi PIP. | lettruthringout | investorshub | 04/21/2022 11:57:34 PM |
BioXcel forms oncology subsidiary to free up neuroscience focus | realfast95 | investorshub | 04/21/2022 9:57:34 AM |
BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to | realfast95 | investorshub | 04/21/2022 9:55:43 AM |
OnkosXcel Therapeutics subsidiary gives BioXcel more options | lettruthringout | investorshub | 04/19/2022 11:54:56 PM |
This one is real wacky | Penny chatter | investorshub | 04/19/2022 3:20:15 PM |
Up $1.53 on that news 15 minutes after | realfast95 | investorshub | 04/19/2022 11:15:14 AM |
BioXcel Therapeutics Announces $260 Million Strategic Financing with | realfast95 | investorshub | 04/19/2022 11:12:20 AM |
Chart for the day ending 4-18-22 | realfast95 | investorshub | 04/19/2022 11:07:48 AM |
znewcar1: BTAI 55% v4,6M c36.97 f18M preMH@43 S@32 HOD@40 strong after hours. | znewcar1 | investorshangout | 02/15/2020 3:16:54 AM |
znewcar1: BTAI 26% v1,6M c23.85 f18M H25.04 S@23.26 | znewcar1 | investorshangout | 02/14/2020 5:19:39 AM |
znewcar1: BTAI 22% v1,9M c16.71 f18M H19.89 S16 | znewcar1 | investorshangout | 01/03/2020 9:52:25 PM |
znewcar1: 2018-1227 +80.91% v2,714,733 c4.36 f15,645,545 Some news recent IPO | znewcar1 | investorshangout | 01/19/2019 8:02:05 PM |
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...
NEW HAVEN, Conn., May 21, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that Rob Risinger, M.D., Chief Medical Officer ...